Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative

Launched by CORPORACION PARC TAULI · Mar 17, 2022

Keywords

ClinConnect Summary

According to the annual report of the Spanish Medical Oncology Association (SEOM), in Spain and without differentiating by sex, colorectal cancer will be the cancer with the highest incidence by 2021; with 43.581 new cases estimated for such year, 14.209 of these will be of rectal cancer. In rectal cancer, surgery remains the cornerstone; however, it is already known that local recurrences are frequent. That is why one of the main milestones rectal cancer treatment, is the multimodal therapy approach. It consists of implementing a neoadjuvant chemoradiotherapy treatment (NCRT) prior to surg...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with rectal tumour and selected to initiate NRCT
• • Patient must know the study and sign informed consent.
• • Patient must accept the conditions necessaries to carry out the prehabilitation.
• Exclusion Criteria:
• • Refusal of the patient to sign the informed consent.
• • Baseline pathology that makes it impossible to carry out prehabilitation.
• • Progression of the disease during the study period.
• • Emergency surgery.